Drug Profile
ATSN 101
Alternative Names: ATSN-101; SAR-439483Latest Information Update: 18 Jan 2024
Price :
$50
*
At a glance
- Originator University of Florida
- Developer University of Florida; University of Pennsylvania
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Guanylate cyclase 1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Leber congenital amaurosis
Most Recent Events
- 16 Jan 2024 Atsena Therapeutics announces intention to submit Biologics License Application to US FDA for Leber congenital amaurosis
- 16 Jan 2024 Atsena Therapeutics announces intention to submit marketing application for Leber congenital amaurosis
- 16 Jan 2024 Atsena Therapeutics anticipates receiving Priority Review Voucher for Leber congenital amaurosis